How Much Should Governments Pay For COVID-19 Monoclonal Antibody Therapies?
Executive Summary
US government’s $450m manufacturing commitment for Regeneron’s antibody cocktail and Gilead’s price for remdesivir drive lower expectations on pricing for the antibody treatments, especially since it seems likely there could be several competing products.
You may also be interested in...
Medicare More Than Doubles Payment Rate For COVID Monoclonal Antibody Administration At Home
Regeneron and Eli Lilly have seen limited uptake for their COVID treatments; CMS payment increase addresses concerns that inadequate reimbursement has hampered use of the monoclonal antibody drugs.
Regeneron Calls For More Government-Funding of Biologic Manufacturing While Defending High Industry Prices
COVID-19 pandemic should finally spur US government to build biologic manufacturing capacity that would be ready for emergencies, Regeneron’s top leadership says. At the same time, the company leaders said the public doesn’t appreciate the value of industry’s private investments and needs to be more accepting of medications’ price points.
Pandemic Clinical Trials Need More Top-Down Control, Gottlieb Says
Ex-FDA commissioner offers British platform trials as examples of research done right, as he worries about studies that aren’t going to yield ‘definitive information’ crowding out trials that are more compelling and for more promising COVID-19 therapeutics.